Cost-effectiveness of fenofibrate versus standard care for reducing the progression of diabetic retinopathy: An economic evaluation based on data from the LENS trial
| Title: | Cost-effectiveness of fenofibrate versus standard care for reducing the progression of diabetic retinopathy: An economic evaluation based on data from the LENS trial |
|---|---|
| Authors: | Scotland, G; Tsehaye, M; Styles, C; Logue, J; Sammons, E; Zayed, M; Emberson, J; Wade, R; Wallendszus, K; Stevens, W; Cretney, R; Harding, S; Leese, G; Currie, G; Armitage, J; Preiss, D; Williamson, P; Bodansky, J; Cairns, A; Dickie, S; Hallard, G; Adigwe, GJ; Jones, L; Lyons, T; Mackenzie, I; Neely, D; Wild, S; Young, I; Patel, P; Watkins, A; Staplin, N; Howard, S; Sawyer, K; Taylor, K; Achiri, P; Burke, A; Hurley, S; McChlery, G; Murphy, K; Pickworth, S; Timadjer, A; Gardiner, K; Willett, M; Wincott, L; Beesley, M; Cutting, C; Raj, M; Roure, I; Goonasekera, M; Bagley, G; Whitehouse, A; Brown, G; Bird, K; Halls, H; Cui, G; Daniels, C; Field, A; Goodenough, B; Mostefai, Y; Syed, S; Chamberlain, A; Knott, C; Liew, A; Meek, J; Mistry, M; Wilson, A; Zettegren, P; AitSadi, R; Barton, I; Baxter, A; Berry, C; Kurien, R; Lay, M; Murawska, A; Thompson, J; Young, A; Spata, E; Raff, R; Howard, C; Taggart, D; Connelly, P; Varikkara, M; Blackwell, S; Elliott, F; Locke, J; Sweeney, A; Wood, S; Herlihy, O; Darling, J; Little, J; Bell, E; Boytha, S; Neill, P; Blaikie, A; Beveridge, L; Coventry, T; Fowler, S; Gray, K; Lister, L |
| Publisher Information: | Wiley |
| Publication Year: | 2025 |
| Collection: | The University of Liverpool Repository |
| Description: | Aims: The LENS trial demonstrated that fenofibrate slowed the progression of diabetic retinopathy compared to placebo in participants with early diabetic eye disease. We assessed its cost-effectiveness for reducing the progression of diabetic retinopathy versus standard care from a UK National Health Service perspective. Methods: Resource use and outcome data were collected over follow-up for participants enrolled in LENS. Mean costs were compared at 2 years and per 6-month follow-up (median 4.0 years). Within the trial, cost-effectiveness was assessed in terms of the incremental cost per case of referable disease averted. A microsimulation model, with inputs derived primarily from LENS trial data, was used to assess the incremental cost per quality-adjusted life year (QALY). Results: Fenofibrate resulted in a mean (95% confidence interval) reduction in health service costs of -£254 (−1062 to 624) at 2 years and -£101 (−243 to 42) per 6-month follow-up. This was accompanied by a 4.4% (1.3% to 8.0%) absolute reduction in any referable diabetic retinopathy or treatment thereof at 2 years, and a 27% (9%–42%) relative reduction over follow-up. Modelled over 10 years, fenofibrate use cost an additional £6 per patient for an expected QALY gain of 0.02, costing £406 per QALY versus standard care under base case assumptions. The probability of cost-effectiveness varied from 70% to 79% at a threshold of £20,000 per QALY, depending on the price discount applied to anti-VEGF drugs. Conclusions: Fenofibrate is likely to offer a cost-effective treatment for slowing the progression of diabetic retinopathy in people with early to moderate diabetic retinopathy or maculopathy. |
| Document Type: | article in journal/newspaper |
| File Description: | application/pdf |
| Language: | English |
| ISSN: | 0742-3071 |
| Relation: | https://livrepository.liverpool.ac.uk/3193962/1/Cost-effectiveness%20of%20fenofibrate%20versus%20standard%20care%20for%20reducing%20the%20progression%20of%20diabetic%20retinopathy%20An%20economic%20eval.pdf; Collapse authors list. Scotland, G orcid:0000-0001-5539-8819 , Tsehaye, M, Styles, C, Logue, J, Sammons, E, Zayed, M orcid:0000-0001-9816-983X , Emberson, J, Wade, R, Wallendszus, K, Stevens, W et al (show 90 more authors) , Cretney, R, Harding, S orcid:0000-0003-4676-1158 , Leese, G, Currie, G, Armitage, J, Preiss, D orcid:0000-0003-3139-1836 , Williamson, P orcid:0000-0001-9802-6636 , Bodansky, J, Cairns, A, Dickie, S, Hallard, G, Adigwe, GJ, Jones, L, Lyons, T, Mackenzie, I, Neely, D, Wild, S, Young, I, Patel, P, Watkins, A, Staplin, N, Howard, S, Sawyer, K, Taylor, K, Achiri, P, Burke, A, Hurley, S, McChlery, G, Murphy, K, Pickworth, S, Timadjer, A, Gardiner, K, Willett, M, Wincott, L, Beesley, M, Cutting, C, Raj, M, Roure, I, Goonasekera, M, Bagley, G, Whitehouse, A, Young, I, Brown, G, Bird, K, Halls, H, Cui, G, Daniels, C, Field, A, Goodenough, B, Mostefai, Y, Syed, S, Chamberlain, A, Knott, C, Liew, A, Meek, J, Mistry, M, Wilson, A, Zettegren, P, AitSadi, R, Barton, I, Baxter, A, Berry, C, Kurien, R, Lay, M, Murawska, A, Thompson, J, Young, A, Spata, E, Raff, R, Howard, C, Taggart, D, Connelly, P, Varikkara, M, Blackwell, S, Elliott, F, Locke, J, Sweeney, A, Wood, S, Herlihy, O, Darling, J, Little, J, Bell, E, Boytha, S, Neill, P, Blaikie, A, Beveridge, L, Coventry, T, Fowler, S, Gray, K and Lister, L (2025) Cost-effectiveness of fenofibrate versus standard care for reducing the progression of diabetic retinopathy: An economic evaluation based on data from the LENS trial Diabetic Medicine, 42 (9). e70098-. ISSN 0742-3071, 1464-5491 |
| DOI: | 10.1111/dme.70098 |
| Availability: | https://livrepository.liverpool.ac.uk/3193962/; https://doi.org/10.1111/dme.70098 |
| Rights: | cc_by_4 |
| Accession Number: | edsbas.3EC45364 |
| Database: | BASE |